secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160348
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha doses first patient with TSHA-102 in Phase 1/2 REVEAL trial for Rett syndrome
--------------------------------------------------------------------------------

- First adult patient received TSHA-102, an AAV9 gene therapy using miRARE technology to regulate MECP2.
- Phase 1/2 REVEAL trial: open-label, dose-escalation (5x10^14 vg then 1x10^15 vg) and dose-expansion in adult females.
- Initial safety data from first patient expected at R&D Day on June 28, 2023.
- Study conducted at CHU Sainte-Justine in Montreal, Canada; independent data monitoring committee will review safety at ~6 weeks.
- First time a gene therapy is evaluated clinically for Rett syndrome, per Taysha management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523160348/0001193125-23-160348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523160348/d513071d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer